JPWO2021107035A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021107035A5
JPWO2021107035A5 JP2021561507A JP2021561507A JPWO2021107035A5 JP WO2021107035 A5 JPWO2021107035 A5 JP WO2021107035A5 JP 2021561507 A JP2021561507 A JP 2021561507A JP 2021561507 A JP2021561507 A JP 2021561507A JP WO2021107035 A5 JPWO2021107035 A5 JP WO2021107035A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
soft contact
less
contact lens
lens according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561507A
Other languages
Japanese (ja)
Other versions
JPWO2021107035A1 (en
JP7250167B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/044070 external-priority patent/WO2021107035A1/en
Publication of JPWO2021107035A1 publication Critical patent/JPWO2021107035A1/ja
Publication of JPWO2021107035A5 publication Critical patent/JPWO2021107035A5/ja
Application granted granted Critical
Publication of JP7250167B2 publication Critical patent/JP7250167B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (11)

0.001w/v%以上、0.008w/v%以下のアルキルジアミノエチルグリシン塩酸塩、および、0.3w/v%以上、0.8w/v%以下の金属塩化物を含有するソフトコンタクトレンズ用医薬組成物。 A soft contact lens containing 0.001 w/v% or more and 0.008 w/v% or less of alkyldiaminoethylglycine hydrochloride and 0.3 w/v% or more and 0.8 w/v% or less of metal chloride. pharmaceutical composition for 金属塩化物が、アルカリ金属の塩化物、および、第2族金属の塩化物からなる群より選択される1以上の塩である請求項1に記載のソフトコンタクトレンズ用医薬組成物。 2. The pharmaceutical composition for a soft contact lens according to claim 1, wherein the metal chloride is one or more salts selected from the group consisting of chlorides of alkali metals and chlorides of Group 2 metals. 金属塩化物が塩化ナトリウムおよび/または塩化カリウムである請求項1に記載のソフトコンタクトレンズ用医薬組成物。 The pharmaceutical composition for soft contact lenses according to claim 1, wherein the metal chloride is sodium chloride and/or potassium chloride. 更にブドウ糖を含有する請求項1~のいずれかに記載のソフトコンタクトレンズ用医薬組成物。 The pharmaceutical composition for soft contact lenses according to any one of claims 1 to 3 , further comprising glucose. 0.001w/v%以上、0.01w/v%以下のブドウ糖を含有する請求項に記載のソフトコンタクトレンズ用医薬組成物。 The pharmaceutical composition for a soft contact lens according to claim 4 , containing 0.001 w/v% or more and 0.01 w/v% or less of glucose. 0.001w/v%以上、0.005w/v%以下のアルキルジアミノエチルグリシン塩酸塩を含有する請求項1~のいずれかに記載のソフトコンタクトレンズ用医薬組成物。 The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 5 , containing 0.001 w/v% or more and 0.005 w/v% or less of alkyldiaminoethylglycine hydrochloride . 0.001w/v%以上、0.005w/v%以下のアルキルジアミノエチルグリシン塩酸塩、
0.3w/v%以上、0.8w/v%以下の金属塩化物、および、
0.002w/v%以上、0.008w/v%以下のブドウ糖を含有する請求項1~のいずれかに記載のソフトコンタクトレンズ用医薬組成物。
0.001 w/v% or more and 0.005 w/v% or less alkyldiaminoethylglycine hydrochloride,
0.3 w/v% or more and 0.8 w/v% or less metal chloride, and
The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 5 , containing 0.002 w/v% or more and 0.008 w/v% or less of glucose.
更に緩衝剤を含有する請求項1~のいずれかに記載のソフトコンタクトレンズ用医薬組成物。 The pharmaceutical composition for soft contact lenses according to any one of claims 1 to 7 , further comprising a buffering agent. 緩衝剤の濃度が0.1w/v%以上、2.0w/v%以下である請求項8に記載のソフトコンタクトレンズ用医薬組成物。The pharmaceutical composition for a soft contact lens according to claim 8, wherein the concentration of the buffering agent is 0.1 w/v% or more and 2.0 w/v% or less. pHが5.5以上、8.0以下である請求項1~のいずれかに記載のソフトコンタクトレンズ用医薬組成物。 The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 9 , which has a pH of 5.5 or higher and 8.0 or lower. pHが6.5以上、7.5以下である請求項1~10のいずれかに記載のソフトコンタクトレンズ用医薬組成物。 The pharmaceutical composition for a soft contact lens according to any one of claims 1 to 10 , which has a pH of 6.5 or higher and 7.5 or lower.
JP2021561507A 2019-11-29 2020-11-26 Pharmaceutical composition for soft contact lenses Active JP7250167B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019217422 2019-11-29
JP2019217422 2019-11-29
PCT/JP2020/044070 WO2021107035A1 (en) 2019-11-29 2020-11-26 Pharmaceutical composition for soft contact lens

Publications (3)

Publication Number Publication Date
JPWO2021107035A1 JPWO2021107035A1 (en) 2021-06-03
JPWO2021107035A5 true JPWO2021107035A5 (en) 2022-11-15
JP7250167B2 JP7250167B2 (en) 2023-03-31

Family

ID=76129616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561507A Active JP7250167B2 (en) 2019-11-29 2020-11-26 Pharmaceutical composition for soft contact lenses

Country Status (3)

Country Link
JP (1) JP7250167B2 (en)
CN (1) CN114786650A (en)
WO (1) WO2021107035A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0816042B2 (en) * 1989-08-08 1996-02-21 ロート製薬株式会社 Liquid for contact lenses
JP4524538B2 (en) 2002-04-08 2010-08-18 ライオン株式会社 Ophthalmic composition
JP2013032393A (en) * 2012-11-09 2013-02-14 Rohto Pharmaceutical Co Ltd Eye drop for contact lens containing refrigerative agent
CN110257188B (en) * 2014-02-06 2021-05-04 Jsr株式会社 Liquid for lens, contact lens, and method for producing same

Similar Documents

Publication Publication Date Title
JP2004536137A5 (en)
JP2020138980A5 (en)
EP3650012A4 (en) Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof
JP2017002035A5 (en)
JP2013519688A5 (en)
HRP20070322T3 (en) Pellets containing venlafaxine hydrochloride
JP2009523829A5 (en)
JP2020070301A5 (en)
MA30793B1 (en) PROCESS FOR THE PREPARATION OF NALTREXONE NALKYL HALIDES
WO2008111357A1 (en) Pure chlorine dioxide solution, and gel-like composition and foamable composition each comprising the same
ME01458B (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
JP2008533183A5 (en)
JP2009538268A5 (en)
JP2013511522A5 (en)
JPWO2021107035A5 (en)
JP2004522993A5 (en)
JP2021191802A5 (en)
RU2016138577A (en) Liquid Pharmaceutical Composition
PH12021550335A1 (en) SCALE-DISSOLVING and REMOVING AGENTS AND CLEANING METHOD
TW201236676A (en) Aqueous composition for contact lens
JP2021119164A5 (en)
MX2023010375A (en) Preservative-free contact lens treating solution.
AR107853A1 (en) DETERGENT VERTIBLE SUSPENSION THAT INCLUDES CATALYST GRANULES OF A WHITENING CATALYST
JP2014504628A5 (en)
MX2022012488A (en) Pharmaceutical formulations.